DRR168528
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.370
- SPERMATOGENESIS+0.270
- PEROXISOME+0.260
- APICAL_SURFACE+0.240
- BILE_ACID_METABOLISM+0.210
- CHOLESTEROL_HOMEOSTASIS+0.180
- MYC_TARGETS_V2+0.160
- MYC_TARGETS_V1+0.150
- FATTY_ACID_METABOLISM+0.110
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.510
- IL6_JAK_STAT3_SIGNALING-0.440
- ALLOGRAFT_REJECTION-0.380
- TNFA_SIGNALING_VIA_NFKB-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- COMPLEMENT-0.320
- P53_PATHWAY-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- INFLAMMATORY_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202476 | — | — | 0.854 |
| 2 | SRR8943022 | — | — | 0.846 |
| 3 | SRR8518130 | — | E | 0.814 |
| 4 | BS_YEW22W35 | high-grade glioma | — | 0.814 |
| 5 | SRR26320088 | — | — | 0.813 |
| 6 | SRR23303756 | — | — | 0.810 |
| 7 | SRR650147 | — | — | 0.807 |
| 8 | TCGA-A7-A4SF-01A-11R-A266-07 | — | B | 0.799 |
| 9 | DRR168522 | — | — | 0.799 |
| 10 | SRR1516068 | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |